May 02, 2023
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
May 01, 2023
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Apr 19, 2023
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
Apr 13, 2023
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
Apr 13, 2023
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Mar 29, 2023
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
Mar 29, 2023
Biomea Fusion Announces Proposed Public Offering of Common Stock
Mar 28, 2023
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Mar 28, 2023
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
Mar 23, 2023
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
Displaying 1 - 10 of 14